A sorted past Beta-lactams are the oldest and most widely used class of antibiotics. The first antibiotic, penicillin, which was discovered by Alexander Fleming in 1928, is a beta-lactam. But the oldest antibiotic proved no match for the infectious disease that has been plaguing mankind for at least 3,000 years 3 . By the mid1940s it became clear that penicillin could not treat tuberculosis, and in the 1960s, scientists began to understand why. M. tuberculosis naturally produces an enzyme that chops off the beta-lactam ring that gives the class its name, rendering the drugs useless. However, this enzyme, called beta-lactamase, can be irreversibly blocked by a drug inhibitor such as clavulanate. For decades, researchers have asked whether using an inhibitor to stall the beta-lactamase enzyme could free up betalactams to do their job of disrupting bacterial cell wall production, and recent data point to a firm 'yes' .
The authors of the 2009 paper that ultimately saved Payen's patient did not originally set out to find a new tuberculosis drug. "My lab is a basic science lab, " says John Blanchard, patient was discharged from the hospital with no traces of Mycobacterium tuberculosis in her sputum. Other patients in Payen's clinic who watched the girl's progress wanted the same treatment, and she conceded despite the fact that meropenem is a beta-lactam and beta-lactams are not supposed to work for tuberculosis.
Throughout history, tuberculosis has killed more people than any other infectious disease 2 . Of the 8 million new cases each year, 3.5 % are classified as MDR, meaning they don't respond to two of the drugs in the standard four-drug treatment regimen, rifampin and isoniazid. The rate of MDR-TB jumps to 20% when considering recurring infections, and in some countries, 50% of all tuberculosis cases are MDR.
According to Barbara Laughon, director of Microbiology and Infectious Diseases at the National Institute of Allergy & Infectious Diseases (NIAID) in Bethesda, Maryland and co-chair of the Stop TB Partnership new drug working group, resistant strains have arisen against every currently available tuberculosis antibiotic. Treatment success for extensively drug-resistant (XDR) cases-defined as those that are resistant to first-and secondline drugs-is less than half of that for drugsusceptible tuberculosis; a fact that has fueled the quest for new antibiotic drugs against this global killer. Now, a small trial arranged by the In the spring of 2009, a 14-year-old girl lay close to death in a hospital bed in Brussels, her lungs ravaged from two years of fighting tuberculosis. The girl and her father had fled to Brussels from Chechnya to seek asylum. After two failed rounds of antibiotics, at only 80 pounds, she was admitted to SaintPierre University Hospital in Brussels. Her doctors gave the girl first-line drugs but saw no improvement. They soon confirmed that she carried multidrug-resistant tuberculosis (MDR-TB), which was suspected to have killed her mother a year earlier.
"We had no more hope for this young girl, " says Marie-Christine Payen, an infectious disease specialist at Saint-Pierre. As her patient struggled to survive, Payen read about an unconventional approach that could save the girl's life and open the door to saving many more.
Payen read about an antibiotic called meropenem that was a potent killer of drugresistant bacteria in lab experiments but only when it was used in combination another compound called clavulanate 1 Given the history of tuberculosis resistance to beta-lactams, some thought the results were too good to be true. "Nobody would believe it, " says Hugonnet, who is now a biochemist at the Cordelier Research Center at Pierre and Marie Curie University in Paris. "At the first meeting I went to, a very old and famous tuberculosis researcher said it was 'bullshit' and would never work. "
But Blanchard was not the first to pair beta-lactams with a beta-lactamase inhibitor to combat drug-resistant tuberculosis. It was shown three decades ago that the combination of clavulanate and another beta-lactam, amoxicillin, could kill M. tuberculosis in culture 4 . Amoxicillin-clavulanate (together called Augmentin) is actually listed by the World Health Organization (WHO) as a group 5 tuberculosis treatment, which means that there is not enough data to support its routine use, but it is occasionally used for XDR-TB. In the 1990s, case studies in the US 5 and Japan 6 as well as a small seven-day trial 7 suggested this combination had the potential to help XDR-TB patients. In contrast, a two-day study showed no benefit to taking amoxicillinclavulanate 8 .
In their 2009 study, Blanchard and Hugonnet showed that in a lab dish, the responses of XDR-TB strains to amoxicillinclavulanate were extremely variable, which may explain the inconsistency in humans. Meropenem-clavulanate, however, worked every time. And as Payen released positive results about five more of her patients 9 , it became clear that something set meropenem apart from other beta-lactams.
The reason this works is that unlike amoxicillin, meropenem falls into a group of beta-lactams called carbapenems, which are somewhat resistant to being chopped up by beta-lactamase enzymes. As clavulanate inhibits the enzyme, the combination brings a one-two punch against tuberculosis.
But there is a catch to the case reports. Antibiotic regimens for tuberculosis have traditionally consisted of combinations consisting of at least four drugs to prevent the bacteria from developing resistance to any one of the medications, and thus meropenem-clavulanate has so far only been used simultaneously with other drugs. "It's hard to attribute success to any one drug, " says Keira Cohen, a fellow in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital in Boston.
Studies in mice that tested meropenemclavulanate in isolation have yielded conflicting results. The mouse model for tuberculosis, however, is fraught with problems. "Mice don't really develop the same pathology as people do, " says NIAID chief of tuberculosis research, Clifton Barry. On top of that, mice have a more active form of an enzyme shared by humans that destroys beta-lactams in the blood before the drugs have a chance to reach the infection. Because of this, Barry says "beta-lactams have a long history of failed mouse data in conflict with positive human data. "
In 2013 a study put out by the WHO Collaborating Center for Tuberculosis and Lung Diseases in Tradate, Italy, brought some clout to the scattered case reports by doing a case-control study of 37 patients 10 . They found that adding meropenem-clavulanate to treatment regimens including the secondline drug linezolid were 20-30% more likely to have negative sputum tests within 90 days. However, meropenem-clavulanate has not yet been tested on its own for its ability to kill tuberculosis in humans.
Bringing it to trial
David Barros-Aguirre, GlaxoSmithKline's director of tuberculosis research and scientific director of ORCHID, hopes to remedy this soon by doing a proof-of-concept study in 30 patients that could justify undertaking a largescale clinical trial. ORCHID, which is funded by the European Union's Seventh Framework Program for Research, has brought together researchers across academia and industry with the goal of getting promising tuberculosis treatments into human trials.
Barros-Aguirre became familiar with Hugonnet and his work on meropenemclavulanate over drinks at a tuberculosis meeting in 2009. "They were one of the groups that were ahead of others, " BarrosAguirre says. He invited Hugonnet to join the consortium and work on beta-lactambeta-lactamase inhibitor combinations that ORCHID could bring to clinical trials.
It was clear that before a trial could begin, an oral alternative to meropenem, which must be administered intravenously two to three times a day, had to be identified. Giving a drug intravenously for the six to nine months required to clear a tuberculosis infection is a tall order in the countries where XDR-TB is most prevalent. Hugonnet took on the challenge, and his group settled on an orally available carbapenem called faropenem, which was is unclear. He says that ORCHID's goal is to get them into clinical trials, and if the results are good, it will open doors for anyone to advance the use of beta-lactams in tuberculosis.
As for amoxicillin-clavulanate, Cohen is not ready to write it off because it is already widely available. She is conducting a study at University of KwaZulu-Natal in Durban, South Africa to figure out which genes make some strains of XDR-TB resistant to amoxicillin so that it could be used as a targeted treatment option.
"This is an exciting area, there's so much opportunity here, " Bonomo says. There is a lot of potential, he says, for testing several different beta-lactam-beta-lactamase combinations against MDR-TB. Merck and AstraZeneca are currently testing new betalactamase inhibitors in phase 1 and 2 trials for other bacterial infections. Bonomo is also working on developing a beta-lactamase inhibitor, and Blanchard recently reported that the orally available drug tebipenem could work in meropenem's place 14 .
For now, Payen continues to use meropenem-clavulanate to treat MDR-TB and XDR-TB patients in her clinic in Brussels. She plans to publish her latest data, which show an 80% success rate among the 16 XDR-TB patients who have had it added to their antibiotic regimen. As for the first patient she treated with the combination, Payen says that today, "She is a very beautiful young lady of 19. "
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Diacon will initially test meropenemclavulanate and faropenem-clavulanate individually in a couple of patients with drugsusceptible tuberculosis for two weeks before giving them standard treatment in what is called an early bactericidal activity trial. If the beta-lactam-beta-lactamase combinations reduce the number of live bacteria cultured from the sputum of the first patients, he will recruit more until he has tested each drug combination in 15 patients. Diacon says that he is ready to start once he receives permission from South Africa's Medicines Control Council (MCC). He expects to have all of the data collected by the end of the year if the MCC approval goes smoothly. "The last patient should be discharged before Christmas, " he says.
A new class Diacon says that if clavulanate allows meropenem or faropenem to work, it could add the beta-lactam drug class to the antibiotic arsenal against tuberculosis.
"We need one more new drug with a different mechanism of action to construct a new regimen that would work for everybody, " he says. "That would change the game. " "It's a paradigm shift, " says Robert Bonomo, an infectious disease specialist at Case Western Reserve University in Cleveland. "I think it's about time people start looking at this." He says that combinations of betalactams with beta-lactamase inhibitors are safe and have been used to treat things like ear infections and pneumonia for decades. Second-and third-line tuberculosis drugs, on the other hand, tend to be more toxic than most antibiotics. "As you advance on the resistance spectrum, the drugs available have less evidence of efficacy and more toxicity," says Erica Lessem, assistant director of the TB/HIV Project at the Treatment Action Group in New York.
Beta-lactams may also prove to be less expensive than current MDR-TB and XDR-TB treatments. In low-income countries, bedaquiline and linezolid cost $5 and $8 a pill, respectively 12 , whereas the average cost for amoxicillin in US is less than $2 a pill 13 . Although online prices of faropenem compare to amoxicillin, Barros-Aguirre points out that the cost savings will not be clear until dosage is tested in later clinical trials, which will not be planned until the results of Diacon's study are examined. Diacon says that the real savings come from the fact that the R&D for faropenem is already done.
For his part, Barros-Aguirre says that GlaxoSmithKline's role in the future for these antibiotic combinations for tuberculosis developed by Daiichi Asubio Pharmaceuticals (now Asubio Pharmaceuticals) in Japan in 1985. The now-defunct US pharmaceutical company Replidyne licensed faropenem from Daiichi Asubio in 2006 but failed to acquire FDA approval. At least nine generic versions of the drug are in widespread use throughout Asia for ailments such as skin infections, but it was never tested against tuberculosis.
Hugonnet has found that faropenem kills XDR-TB strains in culture as well as meropenem. However, he is having trouble publishing his work on faropenem in mice for the same reasons mouse work on meropenem was inconclusive. "The only way to convince people is to do it in humans, " he says.
That is precisely what Andreas Diacon, clinical research specialist and head of the Task Applied Science Research Center in Cape Town, South Africa will do. Diacon was commissioned by Barros-Aguirre to test both meropenem-clavulanate and faropenem-clavulanate for their ability to kill M. tuberculosis in patients. The trial, which is aptly named 'Beta-lactams against TB: teaching new tricks to an old dog' , will begin this fall with funding from ORCHID and the European & Developing Countries Clinical Trials Partnership, a Netherlandsbased initiative to support collaborations between researchers in the EU and those in sub-Saharan Africa 11 .
Diacon's clinical research unit exclusively tests tuberculosis drugs, typically in phase 1 trials. The small clinic, which looks like a modest suburban home with a well-kept treecovered lawn from the outside, has done big things. Diacon's team of eight employees has tested many experimental medications and combinations over the last ten years, including Janssen Pharmaceutical's Sirturo (bedaquiline), a treatment in the first new drug class approved for tuberculosis in over 40 years.
